Rapid leptin elevation after initiation of olanzapine?

Neuropsychobiology

Volumn 54, Issue 3, 2007, Pages 182-185

  Wang, Hsuan Chi ^a   Chen, Po See ^a,b   Lee, I Hui ^a,b   Yang, Yen Kuang ^a,b   Yeh, Tzung Lieh ^a,b   Lu, Ru Band ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Leptin; Olanzapine; Schizophrenia; Weight gain

Indexed keywords

LEPTIN; OLANZAPINE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; LEPTIN; MALE; SCHIZOPHRENIA; SEX FACTORS; WEIGHT GAIN;

EID: 33847715889     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099945     Document Type: Article

References (31)

1. Bhana N, Foster RH, Olney R, Plosker GL: Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-161.
2. Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54:565-567.
3. Chen PS, Yang YK, Yeh TL, Lo YC, Wang YT: Nonketotic hyperosmolar syndrome from olanzapine, lithium, and valproic acid co-treatment. Ann Pharmacother 2003;2003:919-920.
4. Haupt DW, Newcomer JW: Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002;53:925-933.
5. Kapur S, Remington G: Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-517.
6. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345.
7. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C: New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003;59:1-6.
8. Figlewicz DP: Adiposity signals and food reward: expanding the CNS roles of insulin and leptin. Am J Physiol Regul Integr Comp Physiol 2003;284:R882-R892.
9. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
10. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-543.
11. Tena-Sempere M, Pinilla L, Gonzalez LC, Dieguez C, Casanueva FF, Aguilar E: Leptin inhibits testosterone secretion from adult rat testis in vitro. J Endocrinol 1999;161:211-218.
12. Campfield LA: Neurobiology of OB protein (leptin): introduction. Front Horm Res 2000;26:1-11.
13. Casanueva FF, Dieguez C: Neuroendocrine regulation and actions of leptin. Front Neuroendocrinol 1999;20:317-363.
14. Melkersson KI, Hulting AL: Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 2001;154:205-212.
15. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B: Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 2003;60:99-100.
16. Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64:598-604.
17. Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vazquez-Barquero JL: Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001;179:59-62.
18. Wetterling T: Weight gain from atypical neuroleptics - an underreported adverse effect? Fortschr Neurol Psychiatr 2000;68:546-556.
19. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y: Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006;20:75-79.
20. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312-314.
21. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E: Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001;21:8-13.
22. Cohen H, Loewenthal U, Matar M, Kotler M: Association of autonomic dysfunction and clozapine: heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 2001;179:167-171.
23. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M: Interactions between leptin and the human sympathetic nervous system. Hypertension 2003;41:1072-1079.
24. Grassi G: Leptin, sympathetic nervous system, and baroreflex function. Curr Hypertens Rep 2004;6:236-240.
25. Grothe DR, Calis KA, Jacobsen L, Kumra S, DeVane CL, Rapoport JL, Bergstrom RF, Kurtz DL: Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000;20:220-225.
26. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP: Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62.
27. Wilson ME, Fisher J, Brown J: Chronic subcutaneous leptin infusion diminishes the responsiveness of the hypothalamic-pituitary-adrenal (HPA) axis in female rhesus monkeys. Physiol Behav 2005;84:449-458.
28. Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289.
29. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-141.
30. Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia (see comment). Am J Psychiatry 2003;160:284-289.
31. Elimam A, Knutsson U, Bronnegard M, Stierna P, Albertsson-Wikland K, Marcus C: Variations in glucocorticoid levels within the physiological range affect plasma leptin levels. Eur J Endocrinol 1998;139:615-620.